Organization and Business Description (Tables)

6 Months Ended

Mar. 31, 2025

Organization and Business Description [Line Items]

Schedule of Consolidated Financial Statements of the Company

The unaudited condensed consolidated financial statements of the Company include the following entities:

Name of Entity	Date of Incorporation		Place of Incorporation	% of Ownership		Principal Activities
Jin Med		January 14, 2020	Cayman Island		Parent	Investment holding
Zhongjin HK		February 25, 2020	Hong Kong		100%	Investment holding
Erhua Med		September 24, 2020	PRC		100%	WFOE, Investment holding
Changzhou Zhongjin		January 26, 2006	PRC		VIE	Design, development, manufacturing and sales of wheelchair and other mobility products
Taizhou Zhongjin		June 17, 2013	PRC		100% controlled subsidiary of the VIE	Design, development, manufacturing and sales of wheelchair and other mobility products
Zhongjin Jing’ao		December 18, 2014	PRC		100% controlled subsidiary of the VIE	Design, development, manufacturing and sales of wheelchair and other mobility products
Zhongjin Kangma		August 21, 2023	PRC		80% controlled subsidiary of the VIE	Sales of wheelchair and other mobility products
Anhui Zhongjin		October 7, 2023	PRC		100%	Newly incorporated – not in operation yet
Kangma Health		February 19, 2025	PRC		100% controlled subsidiary of the Zhongjin Kangma	Newly incorporated – not in operation yet

VIE [Member]

Organization and Business Description [Line Items]

Schedule of Financial Statement Amounts and Balances of the VIE and VIE’s Subsidiaries

The following financial statement amounts and balances of the VIE and VIE’s subsidiaries were included in the accompanying unaudited condensed consolidated financial statements after elimination of intercompany transactions and balances:

	March 31, 2025		September 30, 2024
Current assets	$	38,902,078	$	37,842,016
Non-current assets		1,740,553		1,971,681
Total assets	$	40,642,631	$	39,813,697
Current liabilities	$	20,567,126	$	17,013,879
Non-current liabilities		30,095		96,175
Total liabilities	$	20,597,221	$	17,110,054

Schedule of Revenue

	For the Six Months Ended March 31,
	2025		2024
Net revenue	$	9,881,505	$	10,556,891
Net income	$	207,608	$	2,201,868

Schedule of Cash Flow Statement

	For the Six Months Ended March 31,
	2025			2024
Net cash provided by operating activities	$	2,919,587		$	629,983
Net cash used in investing activities	$	(4,297,134	)	$	(3,560,418	)
Net cash provided by financing activities	$	4,901,089		$	5,692,303